1448326-33-7

Basic information

• Product Name: (S)-5-broMo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-aMine
• Synonyms: (S)-5-broMo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-aMine;3-((S)-1-(2,6-dichloro-3- fluorophenyl)ethoxy)-5- bromopyridin-2-amine;CL054
• CAS NO: 1448326-33-7
• Molecular Formula: C13H10BrCl2FN2O
• Molecular Weight: 380.0397032
• Mol File: 1448326-33-7.mol
• Article Data: 40

Chemical Properties

• Boiling Point: 423.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.643±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.55±0.10(Predicted)
• CAS DataBase Reference: (S)-5-broMo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-5-broMo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-aMine(1448326-33-7)
• EPA Substance Registry System: (S)-5-broMo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-aMine(1448326-33-7)

Safety Data

• Hazardous Substances Data: 1448326-33-7(Hazardous Substances Data)

Usage

General Description

(S)-5-bromo-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine is a chemical compound with the molecular formula C14H11BrCl2FNO. It is a derivative of the pyridine class of organic compounds and contains a bromine, chlorine, and fluorine atom attached to a pyridine ring. The compound also contains an amine group and an ethoxy side chain. This chemical may be used in medicinal chemistry, as a building block for the synthesis of pharmaceuticals, or as an intermediate in organic synthesis. Its specific properties and applications may vary depending on the field of study and research.

Upstream product

• 877397-65-4 (S)‐1‐(2,6-dichloro-3-fluorophenyl)ethanol 
• 39903-01-0 2-amino-3-hydroxy-5-bromopyridine 
• 15128-82-2 3-hydroxy-2-nitropyridine 
• 330156-50-8 (R)-1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol 
• 877397-71-2 (S)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-aminopyridine 
• 691872-15-8 5-bromo-3-hydroxy-2-nitropyridine 
• 74115-13-2 5-bromopyridine-3-ol 
• 290835-85-7 2',6'-dichloro-3'-fluoroacetophenone 
• 756521-08-1 (±)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine 
• 756520-66-8 1-(2,6-dichloro-3-fluorophenyl)ethanol 
• 756520-67-9 (±)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amine 
• 877399-98-9 C₉H₉Cl₂FO₃S 
• 54231-35-5 3-fuoro-2-nitropyridine 
• 35486-42-1 2-amino-3,5-dibromopyridine 

Downstream Products

• 877399-52-5 crizotinib 
• 1613148-19-8 3-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-yl)pyridin-2-amine 

Relevant articles and documents

Novel synthesis method of crizotinib intermediate (by machine translation)

The invention relates to a synthesis method of an organic compound, in particular to a novel synthesis method of a crizotinib intermediate, which comprises the following steps: taking cheap and easily available 2,6 - dichloro -3 - fluoroacetophenone as a starting raw material and reducing the CBS system to obtain S-shaped chiral alcohol. , 2 - Aminopyridine is taken as a raw material and bromine is brominated to obtain 3,5 - dibromo -2 - aminopyridine. The compound is condensed into an ether with a chiral alcohol under the action of an acid-binding agent to obtain the intermediate of the required configuration. The method is simple in reaction, short in route, less in three wastes, environment-friendly, high in yield of all steps, and less in raw material and reagent waste. (by machine translation)

Novel pyridine derivatives having inhibition activity against SHIP2 and pharmaceutical compositions with the components

The present invention relates to a use as a pyridine derivative and/or a SHIP2 inhibitor. More specifically, the present invention relates to: a pyridine derivative of chemical formula I or pharmaceutically acceptable salt thereof; a method for manufacturing compounds thereof; and a pharmaceutical composition containing the compounds as active components. The pyridine derivative and the pharmaceutically acceptable salt thereof are useful as therapeutic agents for diseases related to SHIP2, such as Alzheimerandprime;s dementia, hypertension, cancer, diabetes, etc.COPYRIGHT KIPO 2020

Synthesis of a Crizotinib Intermediate via Highly Efficient Catalytic Hydrogenation in Continuous Flow

Kilogram-scale highly selective catalytic hydrogenation of the aryl nitro group in the intermediate of crizotinib has been developed, which adopted continuous-flow technology with prepassivated Raney Ni as a catalyst at room temperature. According to the reaction condition optimization, side reactions such as dehalogenation, debenzylation, and reduction of other unsaturated functional groups were inhibited eminently. Moreover, catalytic hydrogenation of (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine (compound I) afforded the desired product (R)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine (compound II) with high selectivity (99.9%) and high conversion (99.5%). Finally, high-quality crizotinib was synthesized from intermediate II.